Reimbursed Care Access in Antigua and Barbuda

Currently classified as a strictly controlled substance under Antigua and Barbuda's Misuse of Drugs legislative framework, with no authorised medical use outside of properly approved clinical research or explicit licences issued under the Misuse of Drugs Act and its amendments. National scheduling and enforcement place psilocybin/psilocin and analogous tryptamines within the controlled-drug regime; imports, possession, supply, and cultivation for non‑licensed purposes are criminal offences under the Act. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any MDMA‑related therapeutic access would require specific licence/approval under the Misuse of Drugs Act and relevant Ministry of Health or regulatory processes; there is no public evidence of routine clinical or reimbursed MDMA therapy programs in Antigua and Barbuda. # #.

Esketamine (commercially: SPRAVATO) is a clinically authorised treatment for treatment‑resistant depression in multiple regulatory jurisdictions (example: European Commission/EMA authorisation). #. However, there is no publicly available national medicines register entry or government notification indicating a formal Antigua and Barbuda marketing authorisation or a public reimbursement scheme for esketamine as of the date of this report; therefore routine national reimbursement through public health services is not established. Where esketamine might be accessed, it would typically require (a) registration/marketing authorisation with the national regulatory authority or (b) import/exception licensing under the Misuse of Drugs Act for medical use, plus local institutional arrangements for supervised administration and risk‑mitigation (REMS‑like) protocols. The Misuse of Drugs Act provides the legal framework for licenced medical/specialist import and use of controlled medicines; any esketamine access absent local authorisation would rely on special import/compassionate use pathways and private-pay arrangements. # #.

Ketamine is widely recognised internationally as an essential anaesthetic and is listed on the WHO Model List of Essential Medicines; it is routinely used in clinical settings for anesthesia and emergency/acute care and is available as a licenced medicinal anaesthetic agent in most health systems. # #.

In Antigua and Barbuda, ketamine is controlled under the national Misuse of Drugs framework but is permitted for legitimate medical uses (such as general and procedural anaesthesia) when supplied and administered by licensed healthcare professionals and institutions under the statutory exemptions and licensing provisions of the Misuse of Drugs Act and its amendments. Public reimbursement or formal inclusion on a national reimbursement formulary for ketamine used as an anesthetic would follow standard public procurement/essential medicines practice; however, there is no public evidence of a separate, government‑funded ketamine‑based program for psychiatric indications (e.g., repeated sub‑anesthetic ketamine for depression) or of a standing national reimbursement policy for off‑label psychiatric ketamine infusions. Access for psychiatric (off‑label) use would therefore typically be private‑pay or institutionally arranged, and would need local clinical governance and prescribing oversight consistent with national law. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and DMT‑containing preparations are captured by the Misuse of Drugs Act controls unless a specific licence for research or medical use has been granted. There is no public evidence of licensed therapeutic DMT programs or public reimbursement in Antigua and Barbuda. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Access to 5‑MeO‑DMT would require explicit licences under the Misuse of Drugs Act for research/medical purposes; recreational possession, supply or use is subject to criminal sanction. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised, reimbursed ibogaine‑based treatment program publicly available in Antigua and Barbuda; any importation or clinical use would require explicit governmental/licensing approval under the Misuse of Drugs Act. # #.

Although plant materials themselves occupy a complex international legal space, Antigua and Barbuda's Misuse of Drugs framework controls the principal psychoactive constituents (e.g., DMT) and therefore unlicensed use, importation, or supply of ayahuasca preparations for human consumption would be unlawful except under formal research or licence conditions. Consequently, there is no authorised reimbursed pathway for ayahuasca ceremonies or medical programs in Antigua and Barbuda outside approved clinical research. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Cacti or plant materials containing mescaline may fall under the same controls for human consumption when intended as a psychoactive; any therapeutic or research access would require licences issued pursuant to the Misuse of Drugs Act. # #.

Compounds in the 2C family (phenethylamine psychedelics) are captured by the national Controlled Drugs framework and are treated as strictly controlled substances with no authorised medical use outside approved clinical research. Possession, supply, importation and distribution without licence are offences under the Misuse of Drugs Act. # #.